Literature DB >> 28629996

Production of medically useful nitric monoxide using AC arc discharge.

S R Li1, Y F Huang1, Z Liu2, M H Sui3, J M Liu4, K P Yan1.   

Abstract

Inhaled nitric monoxide (iNO) is increasingly used as a medical treatment for acute respiratory distress syndrome. A course of the existing nitric monoxide (NO) therapy with gas cylinders could cost up to approximately $15,000 for an average of 30.2 h. Moreover, a gas cylinder containing a mixture of N2 and NO may potentially leak NO. The objective of this study is to develop an efficient and cost-effective on-site iNO generation system. In the present setup, NO was generated by using dry air or mixed oxygen/nitrogen (O2/N2) and an AC power source with an output power level of 5-30 W at atmospheric pressure. The simultaneously produced NO2 was eliminated with an ammonium sulfite ((NH4)2SO3) solution. The effects of the O2/N2 ratio, gas flow rate, discharge gap distance, output energy density and electrode structure on NOx concentration and the NO/NO2 ratio are reported. The concentrations of NO and NO2 reached 62 ppm and 3 ppm, respectively, after absorption and dilution at a gas flow rate of 6 L/min. With the present setup, the AC arc discharge produced NOx at a stable concentration for at least 6 h using dry air.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AC arc discharge; Acute respiratory distress syndrome (ARDS); Ammonium sulfite; Nitric monoxide generation

Mesh:

Substances:

Year:  2017        PMID: 28629996     DOI: 10.1016/j.niox.2017.06.006

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  1 in total

1.  Intratracheal injection of nitric oxide, generated from air by pulsed electrical discharge, for the treatment of pulmonary hypertension in awake ambulatory lambs.

Authors:  Binglan Yu; Francesco Zadek; Anna Fischbach; Steffen B Wiegand; Lorenzo Berra; Donald B Bloch; Warren M Zapol
Journal:  Nitric Oxide       Date:  2020-01-23       Impact factor: 4.427

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.